These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6391842)

  • 1. Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis.
    Henschen A; Kehl M; Southan C
    Curr Probl Clin Biochem; 1984; 14():273-320. PubMed ID: 6391842
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.
    Henschen A; Kehl M; Deutsch E
    Hoppe Seylers Z Physiol Chem; 1983 Dec; 364(12):1747-51. PubMed ID: 6667926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital dysfibrinogenemia.
    Rupp C; Beck EA
    Curr Probl Clin Biochem; 1984; 14():65-130. PubMed ID: 6150812
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of human fibrinopeptides by high-performance liquid chromatography.
    Kehl M; Lottspeich F; Henschen A
    Hoppe Seylers Z Physiol Chem; 1981 Dec; 362(12):1661-4. PubMed ID: 7319478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic characterization of inhibition of human thrombin with DNA aptamers by turbidimetric assay.
    Zavyalova EG; Protopopova AD; Yaminsky IV; Kopylov AM
    Anal Biochem; 2012 Feb; 421(1):234-9. PubMed ID: 22056408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of abnormal fibrinogens--introduction of new strategies].
    Matsuda M; Yoshida N; Terukina S; Yamazumi K; Asakura S; Maekawa H
    Rinsho Byori; 1989 Apr; Spec No 81():55-63. PubMed ID: 2754812
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
    Ebert RF; Schreiler WE; Bell WR
    Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
    Rooney MM; Mullin JL; Lord ST
    Biochemistry; 1998 Sep; 37(39):13704-9. PubMed ID: 9753458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
    Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
    Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of engineered fibrinogen variants suggests that an additional site mediates platelet aggregation and that "B-b" interactions have a role in protofibril formation.
    Lounes KC; Ping L; Gorkun OV; Lord ST
    Biochemistry; 2002 Apr; 41(16):5291-9. PubMed ID: 11955079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
    Branson HE; Schmer G; Theodor I; Pirkle H
    Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying thrombin-catalyzed release of fibrinopeptides from fibrinogen using high-performance liquid chromatography.
    Ng AS; Lewis SD; Shafer JA
    Methods Enzymol; 1993; 222():341-58. PubMed ID: 8412803
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
    Ebert RF; Bell WR
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp).
    Brennan SO; Hammonds B; George PM
    J Clin Invest; 1995 Dec; 96(6):2854-8. PubMed ID: 8675656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beta chain of chicken fibrinogen contains an atypical thrombin cleavage site.
    Weissbach L; Oddoux C; Procyk R; Grieninger G
    Biochemistry; 1991 Apr; 30(13):3290-4. PubMed ID: 2009266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Manchester. Detection of a heterozygous phenotype in the intraplatelet pool.
    Southan C; Lane DA; Knight I; Ireland H; Bottomley J
    Biochem J; 1985 Aug; 229(3):723-30. PubMed ID: 4052020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinogenopathies.
    Morse EE
    Ann Clin Lab Sci; 1978; 8(3):234-8. PubMed ID: 350125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The action of thrombin on modified fibrinogen.
    Osbahr AJ
    Thromb Haemost; 1983 Jun; 49(3):208-13. PubMed ID: 6410533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the identity of fibrin(ogen) oligomers appearing during fibrin polymerization.
    Henschen A
    Adv Exp Med Biol; 1990; 281():49-53. PubMed ID: 2102625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.